Key takeaways What is 503A compounding? Quick answer: 503A compounding is when a licensed pharmacy makes a custom medication for an individual patient based on a doctor’s prescription. It’s been regulated under federal law since 1997 and is overseen by state pharmacy boards. The name comes from Section 503A of the Federal Food, Drug, and […]
By Astra Editorial Team
Published:
Updated:
Quick answer: 503A compounding is when a licensed pharmacy makes a custom medication for an individual patient based on a doctor’s prescription. It’s been regulated under federal law since 1997 and is overseen by state pharmacy boards.
The name comes from Section 503A of the Federal Food, Drug, and Cosmetic Act, the federal law that lays out the rules for this kind of compounding. The law has been in place since 1997. It exists because some patients need medications that aren’t available commercially, like a child who needs a liquid version of a drug that only comes as a pill, or someone allergic to an ingredient in the standard formulation.
A 503A pharmacy is licensed by its state’s board of pharmacy. It has to follow United States Pharmacopeia (USP) standards for how medications are made, especially for injectable products where sterility matters. The FDA has jurisdiction over the drugs themselves but doesn’t directly inspect 503A pharmacies the way it inspects drug manufacturers.
Here’s what “legitimate 503A compounding” actually looks like in practice:
Quick answer: 503A pharmacies make custom medications for individual patients and are regulated by state pharmacy boards. 503B outsourcing facilities make larger batches and are directly inspected by the FDA. Both are legal compounding categories but serve different purposes.
| 503A pharmacy | 503B outsourcing facility | |
| Who regulates it | State Board of Pharmacy | FDA |
| What it makes | Patient-specific prescriptions, one at a time | Larger batches, often for healthcare facilities |
| Prescription required for each unit? | Yes | No (allowed to compound in anticipation) |
| Must follow CGMP (manufacturer-level quality standards)? | No | Yes |
| Direct FDA inspections? | No | Yes, on a risk-based schedule |
| Sterility standards | USP 795, 797, 800 | USP standards plus CGMP |
The most useful way to think about the difference between 503A and 503B pharmacies is scale plus oversight.
A 503A pharmacy is the right setup for a patient who needs a specific prescription customized for their needs. A 503B outsourcing facility is the right setup for a hospital that needs hundreds of pre-mixed IV bags ready to use.
For compounded GLP-1 medications today, most telehealth platforms work with 503A pharmacies. Some worked with 503B facilities during the GLP-1 shortage, but the FDA’s April 2026 changes have shifted that landscape.
The reason 503A and 503B exist as separate categories goes back to a 2012 public health disaster.
A Massachusetts compounding pharmacy called the New England Compounding Center (NECC) shipped contaminated steroid injections to clinics across the country. The contamination caused a fungal meningitis outbreak that killed 64 people and sickened hundreds more. NECC was operating like a drug manufacturer (large batches, multiple states) but was regulated like a small pharmacy (state oversight only).
Congress responded in 2013 with the Drug Quality and Security Act, which created the 503B category. The idea was that pharmacies operating at manufacturing scale need manufacturing-level oversight, including direct FDA inspections and the same quality standards real drug manufacturers follow.
The 503A category kept the traditional pharmacy compounding model intact, with state pharmacy boards as the primary regulators. 503B was created as a new federal category for the high-volume, manufacturing-style work that needed tighter oversight.
This history explains why 503A and 503B have different regulatory profiles today. It’s not that 503A is “loosely regulated” by accident. Congress designed it to remain state-regulated, while creating 503B as the federally-regulated alternative for the kinds of compounding that NECC was doing.
Quick answer: A well-run 503A pharmacy is safe, but safety depends on the specific pharmacy, not the regulatory category. PCAB accreditation, USP compliance, and clean state inspection records are the signals to look for.
A well-run 503A pharmacy follows USP 797 for sterile compounding, is accredited by independent organizations like PCAB (Pharmacy Compounding Accreditation Board), tests its products, and has clean inspection records with the state board.
A poorly-run 503A pharmacy may cut corners on sterility, source ingredients from unverified suppliers, or skip the quality testing that catches contamination before it reaches patients.
The regulatory category alone doesn’t tell you which one you’re dealing with.
A 2022 study in the Journal of the American Pharmacists Association found that compounding pharmacies accounted for about 45% of FDA drug recalls between 2012 and 2021. Most of these were for sterility issues, and most originated from a small number of pharmacies operating outside accepted quality standards.
A 2025 review published in the Journal of the Endocrine Society flagged contamination, dosing errors, and unauthorized salt forms as the main risks with compounded GLP-1 specifically.
These risks aren’t evenly distributed across 503A pharmacies. They concentrate on a small number of bad-actor operations. The well-regulated 503A pharmacies that telehealth platforms typically work with have much lower risk profiles.
For you as a patient, 503A as a category is fine, but you should know which specific pharmacy is making your medication and what its quality record looks like.
Every prescription is patient-specific, filled by VialsRx (US-licensed), and reviewed by a clinician at Wasef Health, PC. That’s the framework the FDA’s April 2026 rules were written to protect and the one Astra was built inside.
Start your health profile →Quick answer: “Essentially a copy” is the FDA rule that limits how often 503A pharmacies can compound a near-identical version of an approved drug. A compounded GLP-1 counts as essentially a copy if it has the same active ingredient, similar strength (within 10%), and the same route of administration as Wegovy, Ozempic, Zepbound, or Mounjaro.
Federal law says a 503A pharmacy can’t regularly compound a medication that’s “essentially a copy” of an FDA-approved commercial product. The thinking is that if Wegovy already exists at a specific strength and dose, a pharmacy shouldn’t then be allowed to mass-produce a near-identical version as a workaround.
The FDA’s April 2026 clarification defines “essentially a copy” specifically as if:
This means a compounded semaglutide at 2.4 mg/mL is essentially a copy of Wegovy. A compounded semaglutide at 2.4 mg/mL with vitamin B12 added is still considered essentially a copy in the FDA’s view because the B12 addition doesn’t produce a significant clinical difference.
What does count as not-a-copy:
At the moment, the FDA says a 503A pharmacy can compound up to four prescriptions of any one essentially-a-copy formulation per calendar month. Beyond that, the pharmacy needs a documented clinical reason for each prescription.
This means compounded GLP-1 medications remain available, but only when the prescription reflects real individual clinical judgment. If your provider can document why a specific compounded formulation is clinically appropriate for you (allergy, dose customization, intolerance to a standard ingredient), it’s lawful. If your provider is filling out the same form for every patient with no clinical specificity, regulatory pressure is mounting.
Quick answer: Yes, 503A pharmacies can legally compound GLP-1 medications for individual patients in 2026 when a prescriber documents clinical need. The April 2026 FDA changes restricted 503B bulk compounding but kept 503A patient-specific compounding intact.
This is why the question “is my medication coming from a 503A or a 503B” suddenly matters more than it did a year ago. If you’re getting compounded GLP-1 from a 503B facility right now, your supply may shift over the next year. If you’re getting it from a 503A pharmacy, your access is on stable ground.
Astra (try-astra.com) works with VialsRx, a US-licensed 503A pharmacy.
To know whether the specific 503A pharmacy filling your prescription is one of the good ones, look for these signals:
For more on the questions to ask any compounded GLP-1 provider before signing up, see how compounded GLP-1 works and how to choose a legitimate provider.
503A compounding is a real, regulated category of pharmacy practice with a clear legal foundation and decades of history. The right way to think about 503A isn’t as a category to trust or distrust as a whole. It’s as a regulatory floor that good pharmacies build on and bad pharmacies use as cover. Knowing which specific pharmacy is making your medication, and what its quality record looks like, is the practical question that matters.
For more on how to evaluate any compounded GLP-1 platform, including the specific questions to ask before signing up, see our full guide on compounded GLP-1 medications.
If you’re considering compounded GLP-1 treatment, Astra (try-astra.com) prescribes through licensed clinicians at Wasef Health, PC, and fills compounded prescriptions through VialsRx, a US-licensed 503A pharmacy. Astra names its pharmacy openly because that’s the information you should be asking for from any provider.
Astra was built to meet it, from the pharmacy to the prescriber to what shows up at your door.
Start your health profile Takes about 5 minutes.Yes. 503A pharmacies can legally compound semaglutide for individual patients when a prescriber documents clinical need. The FDA’s April 2026 clarification confirmed this. The “essentially a copy” rule applies, meaning the compounded version needs to involve a real clinical difference for the patient (custom dose, allergy accommodation, intolerance to a standard ingredient).
The active ingredient is the same. The difference is how the pharmacy that makes it is regulated. 503A semaglutide is made by a state-regulated pharmacy for an individual patient. 503B semaglutide is made by an FDA-inspected outsourcing facility, often in larger batches. The April 2026 FDA proposal would limit 503B bulk production of semaglutide, while 503A patient-specific compounding remains available.
Same as with semaglutide: the active ingredient is identical, but the regulatory pathway differs. Most reputable compounded tirzepatide today comes from 503A pharmacies.
Yes, compounded GLP-1 medications remain available through 503A pharmacies that prepare patient-specific prescriptions. The major change in 2025-2026 has been at the 503B level, where bulk compounding has become more restricted.
Neither category is inherently safer. The specific pharmacy matters more than the category. 503B facilities follow stricter manufacturing standards (CGMP) and are inspected directly by the FDA, which can make them safer in theory. But excellent 503A pharmacies often have stronger track records than weaker 503B facilities.
A 503A pharmacy is a regular pharmacy with the added legal authority to compound customized medications. The same state regulations and pharmacist licensing requirements apply. The compounding part is an added capability, not a replacement for normal pharmacy practice.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.